Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
best case for any company is if they buy back shares
RS = share consilidation potentially more bang per share
FS = share dilution, only good if they pay a dividend and continue to grow sales at a heft pace
i once a bought into to company based on a forward split 1:2, the stock spilt and the shares have pretty much flatlined for over a couple of years. no real gains percentage wise, except the dividend.
as far as pinkies and otc, they need to show sales!!
i dont like either but the bottom line will always be if they can sell the cider!
anybody starting to see these products pop up around them. i cant see anything through all the dam snow in upstate in ny!!
the rs will work, if they can sell product and the deals they mentioned in the shareholder letter are legit and signed and product is being moved. the share has tanked because they havent been able to move the product in any significant amounts.
if they RS, and dont announce or release some good sales info then expect the value to tank right back down.
25:1 split ratio is expected, and brings shares down to 12mill which is a good number of shares. they will probably release a 1-3 million more shares to fund whatever deals they have in the works. so total shares would be around 15 mill come the end of the year. and hopefully some solid sales numbers from all products 2-3 million in sales
2 mill in sales
15 mill shares
10x earning
share value 1.33
thats about what the current price of 5cents per share would RS to 1.25
so to maintain that they better have sales projections and contracts to amount to about 2mill, otherwise look for a slow decline in share price.
http://web.tickle.com/tests/superiq/?test=superiqogt
take the test and compare already
top of the list as a sponsor - and
in a good position to earn revenue as opposed to just donating funds to support an excellent cause. If Dnag pulls their s--t together and the share price has a nice steady increase for the rest of 2007 and beyond i will donate to amber alerts!!
we will see in a few months, DR. F
i think it will float at current levels until a RS and then slowly trickle back down.
then again that all depends on what Dick plans on releasing as far as information goes.
could be real boring
or very exciting if some good sales numbers are released
smoking-
what do you think is gonna happen with these guys in next couple of weeks?
a slow increase till the RS?
will they announce good sales numbers or any sales numbers by march?
.015 fatboy!
why do you post the same messages on raging bull and ihub?
from the start of the year until now the stock is up!
.0089 -> .015
feb. 22 is an important date to watch but it wont have much effect on the price. according to stockholders find, the meeting is scheduled from 2-4. so the market will be closed before the news is released. M2gen should get final approval and watch closely the weeks following to see what is announced and any partnerships that may form. that could be exciting times for DNAG.
http://www.flsenate.gov/data/session/2007/Senate/Calendars/Weekly/February%2019.pdf
STRMAP ANALYSIS PRICING:
$135 per person for a STRMAP analysis with a written or electronic report for the genetic profile. (To add this report to your Amber Stick™ which is sponsored by Code Amber, you must select the electronic format.)
what?! so whos on first and whats on second
actually for each amberstick sold, if the parents wish to order the dna sample with an electronic file to add to the flash drive it would cost $135 per person.
Good PR for the company! not just fluff. If they wanted to fluff the PR then Dnag would have said that we except to have X amount of revenue to be generated from the sales and dna tests and X amount of units sold blah blah. those are all fluff numbers and guess.
sponsor for amber alerts Great PR!! huge long term benefits.
now as an investor in DNAG i am assuming that each flash drive sold costs 35 dollars from the pr. of which it has nothing to do with DNAG. and then i would assume that parents would have to send away for the DNA test to DNAG? not sure how it works and cant find much info. DNAG has done the dna tests for schools at 140-250$? each i believe. a discounted fee. i would guess that parents have option of performing the test after purchasing the flash drive.
so 25,000 parents buy the flash drive
each household has about 2 kids
so 50,000 dna test more per year
at 100$ each
another 5$ million revenue for DNAG yearly!
all conservative numbers and yes this is what fluff looks like. but a great revenue source that would squash the need for a RS and support the company!!
Dnag goes long and DEEP!!
The fact that jever never had his order filled most likely means that people are holding at current price .015 and are not willing to sell or dump the stock as you have declared to be happening.
some people look at the glass half full
others are just idiots.
Dnag has potential and the next few months will be interesting no arguing or debating that
interesting reply from chaz - Dr. F
it doesnt matter
the database that m2gen is planning on devoloping is not gonna generate revenue. the tests and products are what will generate revenue. the information is for everyone to use. one of the articles posted stated that m2gen and merck would share the database with others.
"Merck also waived exclusivity on one key issue. Any drug company may use the database to find patients whose cancers may be particularly responsive to new drugs for clinical trials."
share info, speed up clinical trials, so on and so on, everybody wins, even little dnag!!
Like i said it is all great PR for the company! not just fluff. stuff like that wont affect the share price but it puts the company out there, helps people, promotes them in positive way. There is a difference between fluff and good pr
absolutely slojab!
i only hope that these guys can pull it off. its not well known, not alot of investors are interested, and the product is really good! that means to me that their is a good chance to make to alot of money in the long term, short term plays aside. the RS will give them some flexibility for funding, if i see them flooding the market with a ridiculous number of shares, thats not a good sign. Keep a close eye on these guys
looked through those companies quickly, nothing that really differentiates themselves from their respective markets. a wine company, a diet soda company in china. thats what i think makes the Dickens a good longshot to make it. the only other beverage company i hold now is jones soda jsda, and i have held that for over almost four years know. i look for unique brands when investing in a saturated market especially energy drinks, things to stand out. Jones stands out in the soda market with unique flavors and package, has a good niche and solid dist. panera, starbucks target. Dickens needs to do the same. they have a good formula for their drink they have just had a hard time finding their niche with risque sex theme. They can take over the bar scene, with dickens on the gun, not much competition there except of course the big bull in their cans. i will hold for a couple of quarters and see what dick can do.
i agree with slojab. i bought my last bunch at 3c to average down a little further and am pretty much at break even with this thing at around 4-6c. i wish i had gotten out at 10c then bought back at in 2.5 -3c. would have been a great move. good job slojab for getting out when you did.
anyway- this thing is at a good entry point below 10c in my opinion cause is could move pretty rapidly on some good news and sales. the end of Q1 is gonna be key though? if i smell fluff i am probably out. but if they can show sales and solid contracts i'll hang around a little longer.
altar,
i agree, the 22nd is just a budget hearing. if they get approval, then hey have to finalize where to build and so on. The approval is key. cause then they can move forward in planning and so on. maybe they can announce some partners after. i think march will be more fireworks and news
will somebody start a board that just deals with patents
i would like to see m2gen outsource to dnag or pay to use their tech. Dnag has access to the database to advance their cancer pipeline. get biofrontera involved to advance their pipline for skin cancers. all round a nice boost and very reasonable. i hope m2gen can provide a nice stream of revenue for DNAG, nothing to crazy. DNAG needs to bring their products to market to make some serious revenue. Hopefully this will provide funds and a stage to advance everything. all the while a nice increase in shareholder value.
from everything i have read it seems that there is alot of overlap between everyone involved from merck to moffit to dnag. wether it is who worked for who and who was in bed with who. The fact that i am sure merck and moffit know about DNAG and what they have been doing is enough to keep me interested. Huge potential, even if they get just a small contract to run samples and profile. it would be great to see Dnag in bed with merck! and as our pipeline continues to devolop the potential is unimaginable.
the year and half they were discussing this with merck overlaps with dnags work with moffit, right?
Dnag can offer a great amount of service and info that can be attached to each dna/tumor sample
Merck Deal With Moffitt Center Benefits Both
KRIS HUNDLEY
c. 2007 St. Petersburg Times
Distributed by The New York Times Syndicate
More Health News Headlines: · Bush Budget Would Cut Domestic Programs · Three Natural Ways To Lower Blood Pressure · Depression Linked To Early Heart Disease · Texas Governor First To Require Girls To Receive HPV Vaccine · Florida Governor Occupies Stem Cell Midpoint · Merck Deal With Moffitt Center Benefits Both · Ex-NFL Lineman Prone To Heart Disease, Study Says
Dr. Timothy Yeatman, professor of surgery at H. Lee Moffitt Cancer Center and Research Institute in Tampa, has been studying the biological markers of cancerous tumors for about eight years, gathering tissues and doing genetic analyses.
Over that time, the technology has improved dramatically, boosting scientists' ability to analyze more genetic data faster. And through Moffitt's Total Cancer Care program, which Yeatman directs, more than 3,000 patients from around the state have agreed to donate their tumor tissues.
While patients' identities are confidential, the tissue samples are linked to personal clinical information about the progress of the donor's disease and how it has responded to specific therapies. Researchers' goal: Identify the genetic "fingerprints" unique to certain tumors and develop drugs that target those specific markers.
As the opportunities have grown, so too has the cost. Moffitt, which received nearly $54-million in funding last year, has invested about $20-million in the effort. But costs for everything from processing the tissue samples to creating a data warehouse were quickly overwhelming Moffitt's best intentions. Which is why Yeatman, 48, was thrilled with the partnership drugmaker Merck & Co. recently signed with Moffitt.
"They're funding the project with a five-year commitment," he said. "We never could have done this much, this quickly, without Merck."
Merck is reportedly contributing $65-million in cash and $30-million of in-kind services to the arrangement. The county has promised, but not yet approved, up to $28-million for the project. In late January, the state also delayed approval of its $15-million contribution to the incentive package. The city of Tampa has agreed to contribute $800,000 cash and land valued at $1.2-million. The public funds will allow Moffitt to buy an undisclosed site near its current campus adjacent to the University of South Florida and build a facility to house M2Gen, the for-profit Moffitt subsidiary which will operate the tissue bank.
Yeatman said the drugmaker will be paying for personnel as well as contributing information technology and gene processing expertise. In exchange, Merck will share access to the one-of-a-kind database with Moffitt's researchers. It will be the only pharmaceutical company to have such access.
Yeatman said the Merck deal, 18 months in the making, was carefully constructed to avoid conflicts of interest. "We felt that if each party received value in different ways, conflicts would be less apt to happen," he said.
But critics of such ties between pharmaceutical companies and nonprofit research groups warn of possible pitfalls. Merck's handling of early Vioxx trials is cited as a classic example of how financial conflicts of interest can skew scientific research. When a study found that patients on Vioxx were three times more likely to have heart attacks than patients on Naproxen, Merck-funded scientists decided it was because Naproxen prevented heart attacks. It wasn't until four years later that Merck pulled Vioxx off the market because of concerns it increased risk of heart attacks.
Merrill Goozner, with the Center for Science in the Public Interest in Washington, D.C., said researchers' deals with drugmakers often come with strings attached. "And the strings can be debilitating," he said. "These restrictions can become the long arm of the private sector reaching in and acquiring public sector funds for its own purposes."
A Merck spokeswoman said it was a stretch to mention the Vioxx controversy in association with the Moffitt partnership.
"We are a responsible company," said Merck's Janet Skidmore. "This partnership is aimed at delivering ultimately greater knowledge about cancer and developing new medicines to treat people."
Moffitt's Yeatman said safeguards are built into Moffitt's drug trials that eliminate the chance for conflicts due to financial interests. And Merck has agreed to share intellectual property and royalties from any drug discoveries that might emerge from collaborative research.
"That's important because the cancer center is looking for ways to increase funds for research," Yeatman said of future royalties, which would be funneled back to Moffitt through M2Gen.
Merck also waived exclusivity on one key issue. Any drug company may use the database to find patients whose cancers may be particularly responsive to new drugs for clinical trials.
"Now we can find patients with the right profiles on day one," he said. "It's a revolutionary concept."
Yeatman said the matching process will give patients faster access to potentially lifesaving drugs. Drugmakers, meanwhile, will save money by getting their drugs tested on a specially targeted group.
"If clinical trial matching proves as valuable as we think it will, it will create a revenue stream for us," Yeatman said. "And opening up the database for matching purposes was never an issue with Merck."
Q&A: The Moffitt-Merck deal
What is it?
Merck & Co. is partnering with H. Lee Moffitt Cancer Center and Research Institute in Tampa to develop a cancer tissue databank that will be run by a for-profit Moffitt subsidiary, M2Gen.
Who gets what?
Moffitt gets a Big Pharma partner that will help speed development of the databank, which will contain genetic profiles of cancerous tumors as well as critical clinical information. Both Moffitt and Merck researchers will have access to the data to develop new drugs, sharing future royalties.
Who pays what?
Merck is contributing $65-million cash and $30-million in-kind services. Public funds include $15-million from the state, up to $28-million from the county and $800,000 cash plus land valued at $1.2-million from the city of Tampa. Neither state nor county officials have yet approved their contributions.
What's the status?
Neither state nor county officials have approved their contributions to the incentive package. The site of M2Gen's new facility also has not yet been disclosed.
Published February 6, 2007
yeah i agree i didnt attend the meeting. but i heard that they were discussing the RS and i know dick was trying to get funding for a buyback but i guess that fell through. as far as i know the letter is the first formal indication that the RS is what he wants to do.
ballz
time will tell with this, just like all the rest. It appears though that they have a solid plan, and team put together for a pinky stock. i feel good holding this one. but have been wrong before.
i have been trying to put together a timeline in my head of when all this stuff has been planned out by merck, moffitt and everyone else. when did you guys first hear about the m2gen company. in articles i have read they were planning this upto 4 years ago! while dnag and moffit were working together.
i will be holding and waiting to see what happens in the next few months. if is splits at 5-6 cents then the price should be 1.25. With good news it should support the value and drive away most of the penny traders. I always had this one as a long. i just hope i was right. Dick better plan on taking this off the pinks real soon to. especially after the RS
it would be nice to see them chop the shares to 12 million and actually start producing some revenue. it would only move the stock up.
the big news to look for is apparently the new version of the shareholder uplate letter DC News. which he has planned for the end of Q1. if any real action occurs it should be around then with some sales numbers. until then expect trading from 3-6 cents on fluff prs like the new website.
"All of this should be welcomed as fantastic news! Speaking of news, as you know in the past, we provided periodic update in the form of our Dickens Cider Insider. We have made a firm commitment to begin providing that same information to our shareholders on a quarterly basis under the new name DC NEWS, beginning the end of Q1 07. This publication will include the same type of news as before but go much further in providing actual numbers and results. I will say again as I have many times in the past, we will not telegraph our moves as we may have done in the past, but rather only report on what is historical fact. This will be a free online publication and printed versions will be available on a subscription basis. We are committed to turning every aspect of this company around and we ask you for your continued support."
rahrahrahrahrahrah
this may be dicks last chance to establish this company if they cant get some solid sales, or contracts in this quarter, then i am probably done with these guys. Product is just to good.
The only news of the RS was from the shareholder letter. all shareholders should be recieving info in the next few weeks for a vote on the RS and a couple of other matters. which dont matter since Dick is the main shareholder. I wouldnt expect the RS to take place until the end of march early april. that just my guess though. there has been no formal release and he has to at least hold the vote before he can do it. but it does seem that there is no stopping it and just a question of when.
slojab you have got time to watch this thing. .03 did appear to be the basement for this thing though. as it held there for quite awhile with little to no news. i have been sitting on a nice pile of stock that have accumulated and flipped and taken a small profit from. i wouldnt buy anymore till i see sales figures. which we should hopefully see the end of march.
i cant wait for the ancestory dna testing on anna nicole smiths daughter. should be real interesting with three possible fathers and one strung out mom. Good chance for dnag to get some PR, here hhuhhuhuh
Good - more shares for me
gotta have patience with this one
excellent long term hold
rare for a pinky
The RS will drop if they dont report any sales or contracts. if they have signed contracts and money coming in then i wouldnt expect much of a drop in the post rs shares. I am waiting for the DC news letter at the end of Q1. so hopefully they will be able to release some sales figures from roach coaches, bars, national dist. etc. that info is more important thant he RS. Sales, sales, sales. only thing that will effect stock price. till then i hold
i get the feeling that dick and boys have been busy and hopefully will have some good info to share at the end of the Q1. i just hope it isnt the fluff that he has been feedin us for the past two years.
stockholder
i agree that the 22nd is the date for the budget committee. and we should see alot of press about m2gen. just give it a few weeks before more info is released about partners, contracts, etc.
I feel real good about the next few months!!
all that is just good PR, its not fluff PR as some on this board think. Helping crime victims, helping people define their ancestory. If you think stuff like that is gonna makethe ps shoot up your not taking in the big picture. These guys have a constant stream of Solid, Positive PR helping people. Big pharma would love that, and not being sued and dragged through the mud for their meds. Big Picture!
the stats for complications from prescribtion meds is through the roof. imagine in years from now when they could release data showing a decrease in side effects, fatalties because of personalized medicine!!